TearClear Closes $22M in Series B Funding Round

TearClear Closes $22M in Series B Funding Round

Led by Chief Executive Officer Robert Dempsey, TearClear is an emerging ophthalmic pharmaceutical company with the purpose of transforming the way current topical medications are delivered to the ocular surface

FREMONT, CA: TearClear, a Boston, MA-based ophthalmic pharmaceutical company, raised $22M in a Series B funding round.

Investors included Bluestem Capital, Visionary Ventures, and Flying L Partners, who collaborated with Falcon Vision, a platform formed by KKR to advance innovation in ophthalmology.

The company plans to use the capital to advance multiple clinical programs in development, with two lead candidates in glaucoma, paving the way for future indications.

Led by Chief Executive Officer Robert Dempsey, TearClear is an emerging ophthalmic pharmaceutical company with the purpose of transforming the way current topical medications are delivered to the ocular surface.

The company also declared the appointment of Stuart Raetzman, who most recently served as Chief Executive Officer of Galderma, to the TearClear Board of Directors. “Stuart is a life science industry executive with proven success in pharmaceuticals, biologics, medical devices and over‐the‐counter products. His appointment further strengthens our Board and his commercial expertise will be a tremendous value to the team,” commented TearClear Chief Executive Officer, Robert Dempsey.

“Eye care professionals have long recognized the negative effects of preservatives on the ocular surface. TearClear is the only pharmaceutical company to administer preservative free eye drops to the ocular surface that are preserved safely prior to administration,” stated Raetzman. “I’m excited to join the Board of TearClear to help bring their versatile platform through regulatory approval and to market.”